Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$32.76 - $39.56 $1.39 Million - $1.68 Million
-42,485 Reduced 40.01%
63,710 $2.23 Million
Q4 2023

Feb 14, 2024

BUY
$14.5 - $38.0 $1.12 Million - $2.94 Million
77,242 Added 266.78%
106,195 $4.04 Million
Q3 2023

Nov 14, 2023

BUY
$15.75 - $26.31 $52,038 - $86,928
3,304 Added 12.88%
28,953 $531,000
Q2 2023

Aug 11, 2023

SELL
$16.96 - $27.82 $771,459 - $1.27 Million
-45,487 Reduced 63.94%
25,649 $665,000
Q1 2023

May 16, 2023

BUY
$18.45 - $27.14 $1.02 Million - $1.5 Million
55,262 Added 348.13%
71,136 $1.34 Million
Q4 2022

Feb 14, 2023

SELL
$20.18 - $33.33 $587,096 - $969,669
-29,093 Reduced 64.7%
15,874 $391,000
Q3 2022

Nov 14, 2022

BUY
$11.58 - $24.73 $159,919 - $341,521
13,810 Added 44.32%
44,967 $807,000
Q2 2022

Aug 15, 2022

SELL
$8.52 - $25.26 $8,451 - $25,057
-992 Reduced 3.09%
31,157 $354,000
Q1 2022

May 16, 2022

SELL
$19.89 - $43.18 $251,548 - $546,097
-12,647 Reduced 28.23%
32,149 $716,000
Q4 2021

Feb 14, 2022

BUY
$26.75 - $46.02 $1.2 Million - $2.06 Million
44,796 New
44,796 $1.96 Million

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.